TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Fluticasone 500mcg BD via accuhaler or identical placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid
D: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
C: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
D: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Brief Summary: The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.


Options:
A: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
B: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia
Brief Summary: Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.


Options:
A: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Intervention Type: OTHER; Name: maintained antipsychotic treatment vs. stepwise drug discontinuation; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol, Risperidone (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol, Risperidone (drug) | Intervention Type: DRUG; Name: Haloperidol, Risperidone (drug); Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia
Brief Summary: After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year. Under both conditions prodrome based early intervention take place.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Intervention Type: OTHER; Name: maintained antipsychotic treatment vs. stepwise drug discontinuation; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: dosing; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol, Risperidone (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol, Risperidone (drug) | Intervention Type: DRUG; Name: Haloperidol, Risperidone (drug); Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome
Brief Summary: Aim of study: To investigate whether four months of metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic-sperm-injection) might increase clinical pregnancy rate in normal-weight (body mass index \[BMI\] below 28 kg/m3) in PCOS (polycystic ovarian syndrome) women.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
D: Arm Label: Metformin-treated group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin-treated group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome
Brief Summary: Aim of study: To investigate whether four months of metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic-sperm-injection) might increase clinical pregnancy rate in normal-weight (body mass index \[BMI\] below 28 kg/m3) in PCOS (polycystic ovarian syndrome) women.


Options:
A: Arm Label: atosiban; Type: EXPERIMENTAL; Interventions: Drug: atosiban | Arm Label: 0.9% salain; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: atosiban; Assigned to Arm(s): atosiban | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): 0.9% salain
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo administration | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Experimental group | Intervention Type: DRUG; Name: Placebo administration; Assigned to Arm(s): Control group
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin, Placebo
D: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome
Brief Summary: Aim of study: To investigate whether four months of metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic-sperm-injection) might increase clinical pregnancy rate in normal-weight (body mass index \[BMI\] below 28 kg/m3) in PCOS (polycystic ovarian syndrome) women.


Options:
A: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
B: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
C: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
Brief Summary: The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PEPT | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: CBO standard | Intervention Type: PROCEDURE; Name: PEPT; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CBO standard; Assigned to Arm(s): 2
C: Arm Label: Spinal Cord Stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Spinal Cord Stimulation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Spinal Cord Stimulation; Assigned to Arm(s): Spinal Cord Stimulation
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
Brief Summary: The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
C: Arm Label: Pregablain CR tablet 82.5 to 660mg; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregablain CR tablet 82.5 to 660mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: pregabalin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (unspecified) | Intervention Type: DRUG; Name: Comparator: pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy
Brief Summary: The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Medtronic Manufactured Spinal Cord Stimulators; Assigned to Arm(s): N/A
D: Arm Label: scs high-frequency; Type: EXPERIMENTAL; Interventions: Device: Device: Precision Novi™ system Neurostimulation procedures | Arm Label: scs tonic; Type: EXPERIMENTAL; Interventions: Device: Device: Precision Novi™ system Neurostimulation procedures | Arm Label: scs burst; Type: EXPERIMENTAL; Interventions: Device: Device: Precision Novi™ system Neurostimulation procedures | Arm Label: scs off; Type: PLACEBO_COMPARATOR; Interventions: Device: Device: Precision Novi™ system Neurostimulation procedures | Intervention Type: DEVICE; Name: Device: Precision Novi™ system Neurostimulation procedures; Assigned to Arm(s): scs burst, scs high-frequency, scs off, scs tonic

Answer: B